Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic study of Bendamustine as a component combination regimen R-B(O)AD for the Treatment of Primary Central Nervous System Lymphoma (Pcnsl)

Trial Profile

Pharmacokinetic study of Bendamustine as a component combination regimen R-B(O)AD for the Treatment of Primary Central Nervous System Lymphoma (Pcnsl)

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs Bendamustine (Primary) ; Cytarabine; Dexamethasone; Rituximab; Vincristine
  • Indications Lymphoma
  • Focus Pharmacokinetics
  • Most Recent Events

    • 23 Jul 2018 New trial record
    • 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top